May 16th, 2019, Exelixis and Iconic Therapeutics enter into exclusive option, and license agreement for novel ADC, ICON-2 worth $7.5M
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://vertassets.blob.core.windows.net/download/ca12d6e5/ca12d6e5-f84e-42ac-a8ba-a5ee34d36096/appendix_figure_2_adc_graphics_revised.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (1)
Alternatively, you can try searching for similar contracts:
